<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioScreening.net &#187; Peptide Research</title>
	<atom:link href="http://www.bioscreening.net/category/news/peptide-research/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.bioscreening.net</link>
	<description>BioScreening news and events</description>
	<lastBuildDate>Thu, 29 Dec 2011 08:21:20 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3</generator>
		<item>
		<title>Company and People Notes: Patheon and Solvias Form Alliance; AstraZeneca Appoints Rich Fante President of US Business; More&#8230;</title>
		<link>http://www.bioscreening.net/2008/11/26/company-and-people-notes-patheon-and-solvias-form-alliance-astrazeneca-appoints-rich-fante-president-of-us-business-more/</link>
		<comments>http://www.bioscreening.net/2008/11/26/company-and-people-notes-patheon-and-solvias-form-alliance-astrazeneca-appoints-rich-fante-president-of-us-business-more/#comments</comments>
		<pubDate>Wed, 26 Nov 2008 17:38:21 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[Peptide Research]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2008/11/26/company-and-people-notes-patheon-and-solvias-form-alliance-astrazeneca-appoints-rich-fante-president-of-us-business-more/</guid>
		<description><![CDATA[Nov 20, 2008 ePT&#8211;the Electronic Newsletter of Pharmaceutical Technology Company Notes San Jose, CA (Nov. 14)â€”AnaSpec established a new facility dedicated to peptide production that complies with good manufacturing practice (GMP). The new facility is adjacent to AnaSpecâ€™s headquarters and provides 5000 ft2 of dedicated GMP space, including two Class 10,000 cleanrooms. AnaSpec produces GMP [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2008/11/26/company-and-people-notes-patheon-and-solvias-form-alliance-astrazeneca-appoints-rich-fante-president-of-us-business-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>AnaSpec Introduces New SensoLyteTM MMP ELISA Kits</title>
		<link>http://www.bioscreening.net/2008/10/23/anaspec-introduces-new-sensolytetm-mmp-elisa-kits/</link>
		<comments>http://www.bioscreening.net/2008/10/23/anaspec-introduces-new-sensolytetm-mmp-elisa-kits/#comments</comments>
		<pubDate>Thu, 23 Oct 2008 18:46:07 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Peptide Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Proteomics]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2008/10/23/anaspec-introduces-new-sensolytetm-mmp-elisa-kits/</guid>
		<description><![CDATA[San Jose, CA October 16, 2008 Matrix metalloproteinases (MMPs) belong to a family of secreted or membrane-associated zinc endopeptidases involved in both normal and diseased tissue remodeling. They are capable of degrading all kinds of extracellular matrix (ECM) proteins, but also can process a number of bioactive molecules. MMPs are key players in normal and [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2008/10/23/anaspec-introduces-new-sensolytetm-mmp-elisa-kits/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BNC Collaborators Author High-profile Paper in Nature Nanotechnology</title>
		<link>http://www.bioscreening.net/2008/10/23/bnc-collaborators-author-high-profile-paper-in-nature-nanotechnology/</link>
		<comments>http://www.bioscreening.net/2008/10/23/bnc-collaborators-author-high-profile-paper-in-nature-nanotechnology/#comments</comments>
		<pubDate>Thu, 23 Oct 2008 18:28:26 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[Nanotechnology]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Peptide Research]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2008/10/23/bnc-collaborators-author-high-profile-paper-in-nature-nanotechnology/</guid>
		<description><![CDATA[London, UK â€“ 17 October 2008: Research by scientists collaborating with specialist product development consultancy, Bio Nano Consulting (BNC), into the workings of vancomycin &#8211; one of the few antibiotics that can be used to combat increasingly resistant infections such as MRSA &#8211; has been published in Nature Nanotechnology (October 2008). The researchers, led by [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2008/10/23/bnc-collaborators-author-high-profile-paper-in-nature-nanotechnology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biological Drugs Spurring an Evolution in Injectable Drug Delivery</title>
		<link>http://www.bioscreening.net/2008/01/03/biological-drugs-spurring-an-evolution-in-injectable-drug-delivery/</link>
		<comments>http://www.bioscreening.net/2008/01/03/biological-drugs-spurring-an-evolution-in-injectable-drug-delivery/#comments</comments>
		<pubDate>Thu, 03 Jan 2008 23:48:35 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[DNA Reasearch]]></category>
		<category><![CDATA[Equipment & Supplies]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Peptide Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Proteomics]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2008/01/03/biological-drugs-spurring-an-evolution-in-injectable-drug-delivery/</guid>
		<description><![CDATA[(Amherst, NH) &#8211; The success of recombinant protein drugs such as Enbrel, Remicade, and Herceptin in treating refractory conditions is fueling the search for protein and peptide-based therapeutic agents in oncology, inflammation and a host of other disease classes. Led by the proliferation of antibody-based drug candidates, biological drugs as a class continue to outpace [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2008/01/03/biological-drugs-spurring-an-evolution-in-injectable-drug-delivery/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bio-Synthesis Contracted to Produce Peptides Derived from Colostrum</title>
		<link>http://www.bioscreening.net/2007/11/30/bio-synthesis-contracted-to-produce-peptides-derived-from-colostrum/</link>
		<comments>http://www.bioscreening.net/2007/11/30/bio-synthesis-contracted-to-produce-peptides-derived-from-colostrum/#comments</comments>
		<pubDate>Sat, 01 Dec 2007 01:13:28 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[North America]]></category>
		<category><![CDATA[Peptide Research]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2007/11/30/bio-synthesis-contracted-to-produce-peptides-derived-from-colostrum/</guid>
		<description><![CDATA[Bio-Synthesis Inc. was contracted by Georgia Cosmetics, Houston, Texas to produce a series of peptides derived from colostrum. Â Georgia Cosmetics have filed for patents encompassing said peptides. Â Colostrum is the early motherâ€™s milk thought to be important in providing the newborn with the elements necessary to establish the immune system of the child. Â Dr. Jersey [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2007/11/30/bio-synthesis-contracted-to-produce-peptides-derived-from-colostrum/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PepCon-2008 Shenzhen, China on April 22-24, 2008</title>
		<link>http://www.bioscreening.net/2007/11/04/pepcon-2008-shenzhen-china-on-april-19-21-2008/</link>
		<comments>http://www.bioscreening.net/2007/11/04/pepcon-2008-shenzhen-china-on-april-19-21-2008/#comments</comments>
		<pubDate>Mon, 05 Nov 2007 00:51:30 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Asia]]></category>
		<category><![CDATA[Peptide Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Proteomics]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2007/11/04/pepcon-2008-shenzhen-china-on-april-19-21-2008/</guid>
		<description><![CDATA[Advances in peptide and protein researches are occurring at an ever increasing pace, in a wide range of fields and scientific disciplines. At this exciting time, it is especially important to promote scientific and technological exchange and cooperation at the international level. To establish of a new educational and networking platform for protein and peptide [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2007/11/04/pepcon-2008-shenzhen-china-on-april-19-21-2008/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

